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CLN2 disease is one of a group of lysosomal storage disorders called the neuronal ceroid lipofuscinoses
(NCLs). The disease results from mutations in the TPP1 gene that cause an insufﬁciency or complete lack
of the soluble lysosomal enzyme tripeptidyl peptidase-1 (TPP1). TPP1 is involved in lysosomal protein
degradation, and lack of this enzyme results in the accumulation of protein-rich autoﬂuorescent lyso-
somal storage bodies in numerous cell types including neurons throughout the central nervous system
and the retina. CLN2 disease is characterized primarily by progressive loss of neurological functions and
vision as well as generalized neurodegeneration and retinal degeneration. In children the progressive
loss of neurological functions typically results in death by the early teenage years. A Dachshund model of
CLN2 disease with a null mutation in TPP1 closely recapitulates the human disorder with a progression
from disease onset at approximately 4 months of age to end-stage at 10e11 months. Delivery of func-
tional TPP1 to the cerebrospinal ﬂuid (CSF), either by periodic infusion of the recombinant protein or by a
single administration of a TPP1 gene therapy vector to the CSF, signiﬁcantly delays the onset and pro-
gression of neurological signs and prolongs life span but does not prevent the loss of vision or modest
retinal degeneration that occurs by 11 months of age. In this study we found that in dogs that received
the CSF gene therapy treatment, the degeneration of the retina and loss of retinal function continued to
progress during the prolonged life spans of the treated dogs. Eventually the normal cell layers of the
retina almost completely disappeared. An exception was the ganglion cell layer. In affected dogs that
received TPP1 gene therapy to the CSF and survived an average of 80 weeks, ganglion cell axons were
present in numbers comparable to those of normal Dachshunds of similar age. The selective preservation
of the retinal ganglion cells suggests that while TPP1 protein delivered via the CSF may protect these
cells, preservation of the remainder of the retina will require delivery of normal TPP1 more directly to the
retina, probably via the vitreous body.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The CLN2 form of neuronal ceroid lipofuscinosis (NCL) is anology, School of Medicine,
, MO 65212, USA.
(R.E.H. Whiting), jensenc@
du (J.W. Pearce), gillespiel@
issouri.edu (D.E. Bristow),
Ltd. This is an open access article uautosomal recessively inherited, lysosomal storage disorder, usu-
ally with an early childhood onset of symptoms (Mole et al., 2011).
The disease is characterized by vision loss culminating in blindness,
seizures, progressive loss of motor and cognitive function, and
premature death. Neurological and visual symptoms are associated
with widespread, progressive degeneration of the brain and retina.
CLN2 disease results from mutations in the TPP1 gene that cause
deﬁciencies of functional tripeptidyl-peptidase 1 (TPP1), a lyso-
somal enzyme involved in protein degradation. Without functional
TPP1, neurons develop inclusions of abnormal storage material andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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degeneration (Mole et al., 2011).
Multiple forms of NCL occur in people as a result of mutations in
at least 13 different genes (Cotman et al., 2013; Mole and Cotman,
2015; Warrier et al., 2013). NCLs have also been reported in a
number of dog breeds, with causative mutations identiﬁed in the
canine orthologs of genes that contain mutations causing corre-
sponding diseases in people (Gilliam et al., 2015). A disorder anal-
ogous to CLN2 disease was discovered in a miniature long-haired
Dachshund. Genomic DNA sequencing revealed a null mutation in
the canine ortholog to the TPP1 gene (Awano et al., 2006). Dogs
with this mutation produce no functional TPP1 enzyme and
develop symptoms similar to those found in children with this
disease (Awano et al., 2006). Affected dogs also develop multifocal
retinal detachments that increase in size and number as the disease
progresses (Whiting et al., 2015).
Employing the Dachshund model, periodic infusion of recom-
binant TPP1 enzyme into the cerebrospinal ﬂuid (CSF) proved
effective in delaying neurologic symptoms of disease and extending
lifespan (Katz et al., 2014; Vuillemenot et al., 2015; Whiting et al.,
2014). Indeed, this treatment recently completed combined phase
1/2 clinical trials with promising preliminary results (https://
clinicaltrials.gov/ct2/results?term¼CLN2&Search¼Search). How-
ever, this approach to treatment did not delay the progressive loss
of retinal function as measured by electroretinography (Whiting
et al., 2014). More recently, similar success in delaying neurolog-
ical disease progression has been achieved in the dog model using
AAV2-mediated TPP1 gene therapy targeted to cells lining the
ventricles of the brain, again relying on the circulating CSF for
widespread delivery of the enzyme (Katz et al., 2015). Because TPP1
gene therapy was effective in substantially delaying the onset and
progression of neurological signs in TPP1-null Dachshunds, exper-
iments were conducted to determine whether administration of
the AAV2-TPP1 vector to the CSF was also effective in inhibiting
retinal degeneration that has been documented in the TPP1-null
dogs (Katz et al., 2008; Whiting et al., 2013a).
2. Materials and methods
2.1. Animals
Purpose-bred miniature longhaired Dachshunds housed in a
research facility at the University of Missouri were used in this
study. CLN2-affected dogs are homozygous for a one nucleotide
deletion in TPP1 (c.325delC) that causes a shift in the reading frame
and a premature stop codon (Awano et al., 2006). This study in-
cludes additional data obtained from CLN2-affected dogs treated
with CNS gene therapy (n¼ 3; 1 male, 2 females) (Katz et al., 2015).
Data reported by Whiting et al., 2013a are utilized as control data
from normal dogs and untreated, CLN2-affected dogs (Whiting
et al., 2013a). All studies were performed in compliance with the
EU Directive 2010/63/EU for animal experiments and were
approved by the University of Missouri Animal Care and Use
Committee.
2.2. CNS gene therapy treatment
As previously described (Katz et al., 2015), we tested whether
infusion into the CSF of a rAAV2 vector directing expression of
canine TPP1 (AAV2.caTPP1) can provide enzyme replacement
broadly through the brain for clinical beneﬁt. At 11e14weeks of age
TPP1-null Dachshunds (n ¼ 3) received unilateral, intraventricular
injection of rAAV2.caTPP1. This resulted in nearly complete trans-
duction of ependyma lining the lateral ventricles, and additional
transduction of ependyma in the 3rd and 4th ventricles (Katz et al.,2015). Cyclosporine was administered continuously to dogs in this
study starting one to two weeks prior to the gene therapy vector
administration. Dogs were also treated with mycophenolate start-
ing 5 days prior to rAAV.caTPP1 delivery. Mycophenolate adminis-
tration was eventually discontinued after 2e4 months in all of the
dogs.
2.3. Clinical examinations and in vivo retinal imaging
All dogs received a complete ophthalmic examination prior to
inclusion in the study. Animals were excluded from the study if
they exhibited any retinal abnormalities that would compromise
vision prior to the onset of retinal or neurological disease due to
CLN2 disease. Ophthalmic examination was performed monthly on
TPP1/ dogs. Examination consisted of vision-mediated behavior
assessment, slit lamp biomicroscopy and indirect ophthalmoscopy
(Whiting et al., 2015).
In vivo imaging was performed approximately every 2 months
in the left eye of each dog using a combined confocal scanning laser
ophthalmoscope (SLO) and spectral-domain optical coherence to-
mography (OCT) instrument (Spectralis HRA/OCT, Heidelberg,
Germany) (Whiting et al., 2015). SLO fundus images were analyzed
quantitatively with Adobe Photoshop to determine the percentage
of retinal area covered by detachment lesions and were scored as
follows: Grade 1 indicating that less than 15% of the retina was
affected by lesions; Grade 2 indicating that greater than 15% but
less than 30% of the retina was affected by lesions; and Grade 3
indicating that 30% or greater of the retina was affected by lesions
(Whiting et al., 2015).
OCT cross-sectional images were analyzed for total retinal
thickness using the Heidelberg Eye Explorer software. Retinal
thickness measurements were taken at 1 optic disc diameter (OD)
distance superior to the optic nerve head (ONH) and 2OD distance
superior to the ONH for each timepoint. Measurements were also
taken 1OD and 2OD inferior to the ONH. Thickness measurements
were only taken from retina closely apposed to the RPE and not
from areas of the retina affected by localized detachment. Total
retinal thickness values in the treated, CLN2-affected dogs were
compared to those from normal, age-matched Dachshunds.
2.4. Electroretinography and pupillary light response recordings
For two dogs treatedwith CNS gene therapy, ERG recordings and
pupillary light reﬂex (PLR) recordings were performed as previ-
ously described (Whiting et al., 2013a), approximately every two
months between 6 and 14 months of age. PLR recordings were also
performed in one of these dogs at 18 months of age.
ERGs were bilaterally elicited and simultaneously recorded with
a portable unit (HMsERGmodel 2000; RetVet Corp., Columbia, MO).
Each ERG session consisted of scotopic and photopic recordings in
accordance with the Dog Diagnostic Protocol, recommended by the
European College of Veterinary Ophthalmology, primarily for
evaluation of rod and cone function (Ekesten et al., 2013). For each
stimulus condition in a given recording session, the amplitudes
from the right and left eye were averaged to give a single value per
dog for each ﬂash intensity.
All PLR recordings were done during the light period of the daily
12:12 light-dark cycle. The detailed methods for obtaining the PLRs
have been described previously (Whiting et al., 2013b). Recordings
were performed in dark-adapted, anesthetized dogs with a custom
apparatus (Whiting et al., 2013b) which provided timed delivery of
a visible light stimulus from a mounted high-power broad spec-
trum LED (MCWHL2; Thorlabs Inc., Newton, NJ) and concurrently
recorded pupil images at 30 frames per second using an infrared-
sensitive camera (PC164CEX-2; Supercircuits Inc., Austin, TX)
Fig. 1. ERG b-wave amplitudes versus age in CLN2-affected dogs treated with CNS gene
therapy (n ¼ 2) compared with those of normal dogs (n ¼ 7) and those of untreated,
CLN2-affected dogs (n ¼ 5); control data adapted from (Whiting et al., 2013a). Am-
plitudes reﬂect scotopic mixed rod and cone responses after high intensity light ﬂashes
of 13.2 log photons/cm2/s (10 cd.s/m2). Amplitudes from treated affected dogs were
signiﬁcantly reduced from normal by 6 months of age and continued to decline over
time until 12 months of age when no response was detected even at the highest
stimulus intensity (ǂp < 0.05; *p < 0.005). There were no signiﬁcant differences be-
tween treated and untreated CLN2-affected dogs for any of the ages tested. Error bars
represent standard deviation.
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zation of the eye. The direct PLR of the right eye was evaluated
using a standardized protocol of 100 ms ﬂashes of broad spectrum
white light at each of 10 intensities between 8 and 15 log photons/
cm2/s (approximately 0.07 mcd.s/m2 to 65 cd.s/m2). Pupil images
were analyzed in Photoshop, and average PLR constriction ampli-
tude was calculated for each ﬂash intensity.
2.5. Histological analysis
All 3 dogs evaluated in this study were euthanized when they
reached end-stage disease at 16e21 months of age (Katz et al.,
2014). The eyes including at least the ﬁrst 8 mm of the optic
nerves were enucleated within 5 min after euthanasia, and the
corneas were removed immediately. The samples were then ﬁxed
for either the best structural preservation or for immunohisto-
chemistry, and areas of the retina adjacent to the optic nerve heads
were dissected as described previously (Katz et al., 2005). Sections
of the samples were cut at a thickness of 0.6 mm, mounted on glass
slides, and stained with toluidine blue. Digital photographs of the
sections were obtained using conventional transmitted light mi-
croscopy. Areas of the retinas from the posterior pole of an eye from
each dog that were ﬁxed for immunohistochemistry were
embedded in parafﬁn. Sections of the parafﬁn-embedded retinas
were immunostained with a mouse monoclonal anti-TPP1 anti-
body diluted 1:100 (Abcam ab54685). Immunostaining was per-
formed essentially as described previously (Morgan et al., 2013).
2.6. Optic nerve axon number determination
Approximately 3 mm long segments of the EM-ﬁxed optic
nerves obtained from within 1 cm of the back of each globe were
post-ﬁxed in osmium tetroxide and embedded in epoxy resin. Cross
sections of these samples were cut at a thickness of 0.4 mm,
mounted on slides and stained with toluidine blue. Composite high
resolution images of the entire cross section of each optic nerve
were obtained as described previously (Morgan et al., 2014). Axon
numbers were determined using Adobe Photoshop Touch (Adobe
Systems, Inc., San Jose, CA) and Image J (http://rsb.info.nih.gov/ij/)
(Whiting et al., 2014). Images were displayed on an iPad at a suf-
ﬁcient magniﬁcation that each axon could be clearly distinguished.
Using a ﬁne-tipped stylus, a dot was placed over each axon in a
separate image layer in Photoshop. Once all of the axons had been
marked, the image layer consisting of only the dot marks was im-
ported into Image J, which was used to automatically count the
marks.
2.7. Statistical analysis
All statistical tests were performed using SigmaPlot (Systat
Software Inc., San Jose, CA). Datawere subjected to the Shapiro-Wilk
test to conﬁrm normal distribution. Repeated measures 2-way
ANOVAwas used to compare data from CLN2-affected dogs treated
with CNS gene therapy (n ¼ 2) to those from normal TPP1þ/þ dogs
(n ¼ 7) and to those from untreated, CLN2-affected dogs (n ¼ 5) to
determine if the treatment was able to reduce or normalize deﬁcits
in ERG b-wave amplitude or PLR constriction amplitude related to
CLN2 disease progression. Follow-up pairwise comparisons were
performed with the Holm-Sidak correction (a ¼ 0.05) to control
family-wise error rate.
The numbers of axons in the optic nerves of the dogs that
received the CNS gene therapy were compared to the number of
axons from 5 normal Dachshunds of similar age from a previous
study (Whiting et al., 2014). Statistical comparisons were per-
formed using Student's t-test.3. Results
3.1. Retinal function
Dogs treated with CNS gene therapy exhibited progressive
degeneration of ERG waveforms with age (Fig. 1), similar to the
progression of deﬁcits previously observed in untreated CLN2-
affected dogs (Whiting et al., 2013a). By 12 months of age, the
dogs had non-recordable ERGs under scotopic and photopic con-
ditions. PLR constriction amplitudes in treated dogs were also
similar to those of untreated, affected dogs (data not shown). At 10
months of age, neither dog responded to a ﬂash intensity of 10 log
photons/cm2/s, which is consistent with data collected in several of
the untreated, CLN2-affected dogs (Whiting et al., 2013a). This is a
clear contrast to age-matched normal dogs which have an average
constriction amplitude of 41% and to CLN2-affected dogs that
showed a preservation of the PLR after enzyme replacement ther-
apy which had an average constriction amplitude of 45% (Whiting
et al., 2014).
3.2. Retinal structure in vivo
Between 6 and 12 months of age, both treated CLN2-affected
dogs had total retinal thicknesses comparable to that of normal
dogs in both the superior and inferior retina. However, as the dis-
ease progressed during the extended lifespan, superior and inferior
retinal thickness in the treated CLN2-affected dogs decreased. No
statistical comparison between the affectedetreated and normal
dogs could be made at 16 or 18 months since only one dog survived
to these ages (Fig. 2). However, for this dog retinal thickness
declined by 41% in the superior retina and 57% in the inferior retina
between 4 and 18 months of age, whereas there was no decline in
retinal thickness over this age span in the control dogs.
Two CLN2-affected dogs treated with CNS gene therapy devel-
oped disease-related multi-focal retinal detachments, dog A at 10
months of age and dog B at 8 months of age. The appearance of the
lesions in both dogs was initially the same as that previously re-
ported in Dachshunds with the CLN2 disease (Fig. 3A) (Whiting
Fig. 2. Total retinal thickness decreased progressively during the extended lifespan
beyond 12 months of age in gene therapy treated CLN2-affected dogs. While superior
and inferior retinal thickness appears be reduced from normal at 14 months, a sta-
tistically signiﬁcant difference from the normal dogs could not be detected at this age
due to the small sample sizes. Thickness measurements were taken 1 optic disc
diameter (OD) superior to the ONH and 1 OD inferior to the ONH for each timepoint.
Error bars represent standard error of the mean (SEM).
Fig. 4. OCT cross-sectional images showing thinning of the superior and inferior retina
in CLN2-affected dog B at 17 months of age. OCT images from a normal dog of similar
age, taken from comparable locations in the retina, are included for comparison.
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stage disease. However, for dog B the lesions progressed to grade
2 at 10 months of age (Fig. 3A). At 14 months of age, lesions in dog B
began to ﬂatten as the retina showed thinning with cross-sectional
OCT imaging (Fig. 2). As retinal thinning progressed with age, the
previously observed retinal detachments were no longer visible by
17 months of age with SLO (Fig. 3B) or with OCT imaging (Fig. 4).3.3. Retinal histology
By end-stage disease, the retinas of the affected dogs were
extremely thin with none of the normal retinal layers recognizable
(Fig. 5A). Cells with large nuclei were scattered along the vitreal
edge of what remained of the retina with a single row of cells with
smaller, more compact nuclei just exterior to them adjacent to the
underlying retinal pigment epithelium. In order to determine
whether some these remaining cells could be ganglion cells, the
numbers of ganglion cell axons were determined in cross-sections
of the optic nerves from each of the dogs (Fig. 5B and C and Table 1).
The numbers of axons were not signiﬁcantly different from those ofFig. 3. SLO fundus photos from the left eye of dog B at 10 months of age (A) and at 17 month
visible at the later time point due to advanced degeneration and thinning of the retina.the optic nerves from normal Dachshunds of similar age, which
were on average 158,617 ± 16,611 (mean ± SD) (Whiting et al.,
2014). This indicates that despite the obvious dramatic loss of
most cell types from the severely thinned retinas, there was no
signiﬁcant loss of ganglion cells. The selective preservation of the
ganglion cells was not associated with the presence of TPP1 in the
ganglion cell bodies, since TPP1 immunostaining, present in the
ganglion cells of normal Dachshund retinas, could not be detected
by immunostaining in sections of retinas of the treated, affected
Dachshunds at end-stage disease (Fig. 6). In addition to punctate
TPP1 immunostaining in the ganglion cell bodies of the normal dog
retina, there was also substantial TPP1 immunostaining associated
with the photoreceptor outer segments as well as diffuse immu-
nostaining throughout the retina (Fig. 6A).s of age (B). Retinal detachments that are present at the earlier time point are no longer
Fig. 5. (A) Light micrograph of cross-section of the retina from Dog B from a region of the central retina. (B) A composite high resolution light micrograph of a cross-section of the
optic nerve from Dog C. (C) A digitally magniﬁed region of the area of the image in (B) indicated by the yellow rectangle demonstrating that the composite image had sufﬁcient
resolution to enable each individual axon in the composite image to be distinguished and counted.
Table 1
Numbers of axons in optic nerve cross sections of 3 TPP1/ dogs that received
intracerbroventricular TPP1 gene therapy.




*Normal: 158,617 ± 16,611 (n ¼ 5; mean ± SD) (Whiting et al., 2014).
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In the Dachshund model of CLN2 disease, dogs lack the lyso-
somal enzyme TPP1 due to a null TPP1 mutation, which results in
progressive degeneration of the CNS and retina (Katz et al., 2008,
2014; Whiting et al., 2015). Untreated dogs with CLN2 disease
must be euthanized by 10e11 months of age due to the severity of
the neurological signs. At this age there is signiﬁcant loss of retinal
function and thinning of the inner retina but no signiﬁcant loss of
retinal ganglion cells (Katz et al., 2008; Whiting et al., 2015). TPP1
supplied to the CNS via the CSF, either by periodic infusion of the
recombinant enzyme or by administration of a TPP1 gene therapy
vector into the CSF, signiﬁcantly delays progression of neurological
signs and results in substantial lifespan extension in the Dachshund
model. However, we found that this treatment does not delay
retinal degeneration or loss of retinal function, which continue over
the extended lifespans of the dogs until the ERG becomes non-
recordable and the retina becomes only a very thin layer with
none of the normal retina cell layers morphologically recognizable.
One might not expect TPP1 enzyme present in the CSF attherapeutic levels for the brain to reach the majority of the retinal
cell layers. However, the sheath around the optic nerve is contin-
uous with the brain dura, and the space between this sheath and
the optic nerve is continuous with the subarachnoid space through
which the CSF ﬂows. Therefore, it is possible that TPP1 present in
the CSF could be taken up by the retinal ganglion cell axons, of
which the optic nerve is comprised, and thereby preserve the
structure and function of these cells. Indeed, in a previous study we
found that periodic infusion of recombinant TPP1 into the CSF
selectively inhibited the disease-related decline in the pupillary
light reﬂex, suggesting a potential preservation of intrinsically
photosensitive retinal ganglion cells (Whiting et al., 2014).
Therefore, analyses were performed to determine whether
ganglion cells were present in the extremely thin retinas of CLN2-
affected dogs whose life spans had been extended by administra-
tion of the TPP1 gene therapy vector to the CSF which resulted in
sustained elevated CSF levels of TPP1. Since each ganglion cell
contributes one axon to the optic nerve, we determined the
numbers of ganglion cells remaining in the retina at disease end-
stage of the treated dogs by counting the numbers of axons
remaining in cross-sections of the optic nerve. Rather surprisingly,
there was no signiﬁcant difference between the numbers of axons
in the optic nerves of the treated dogs between 71 and 92 weeks of
age and untreated normal Dachshunds that were euthanized at
42e44 weeks of age (Table 1).
We hypothesized that this selective preservation of the ganglion
cells was due toTPP1 uptake from the CSF via their axons. However,
wewere unable to detect any TPP1 immunolabeling in the ganglion
cell bodies from the treated dogs at end-stage disease. In the retinas
from normal dogs, intense punctate TPP1 immunostaining was
Fig. 6. Light micrographs of retinal cross-sections immunostained with an anti-TPP1 antibody. The brown color indicates TPP1 antibody binding. (A) The retina from a normal
Dachshund shows punctate immunostaining in the ganglion cells (arrows in A). (B) Ganglion cells from Dog B did not show any TPP1 immunolabeling (arrow in B). Intense TPP1
immunostaining was also present around the photoreceptor outer segments in the normal dog and diffuse immunostaining was present throughout most of the rest of the retina.
Both retinas were artifactually detached from the retinal pigment epithelium during processing for parafﬁn embedding. Bar in (B) indicates the magniﬁcation of both micrographs.
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normally present in the lysosomes of these cells. Diffuse TPP1
immunolabeling throughout the retinas from normal dogs most
likely represents the protein within the endoplasmic reticulum
where it is synthesized and in transport vesicles that normally
deliver the enzyme to lysosomes and to the cell surface. It is
possible that TPP1 was present in the ganglion cells of the affected
dogs, but at levels below the threshold of detection for IHC. If this is
the case, the TPP1 levels would have been much lower than normal
since TPP1 immunolabeling was easily detectable in the ganglion
cell bodies of normal dog retinas. It is well established that in a
variety of lysosomal storage diseases, even very low levels of
lysosomal enzyme function can be therapeutic (Parenti et al., 2015).
It is also possible that the ganglion cells were able to take up sig-
niﬁcant amounts of TPP1 from the CSF for quite some time after the
CNS gene therapy treatment, but that the amount of enzyme
available from the CSF waned over time as the dogs approached a
belated end-stage disease status. Indeed, CSF levels of TPP1 waned
over time in the dogs that received the TPP1 gene therapy treat-
ment (Katz et al., 2015). If this was the case, retinal ganglion cell
levels of TPP1 may have declined only late in the disease process,
thus explaining the lack of immunolabeling despite preservation of
the cells.
An alternative hypothesis to explain the selective survival of the
ganglion cells is that these cells are simply less sensitive to the
absence of TPP1 than are other retinal neurons. Although TPP1 is
present and involved in protein turnover in most cell types in the
body, CLN2 disease is primarily a neurological disorder with little
evidence of dysfunction of non-neuronal cells which apparently
tolerate the absence of TPP1 fairly well. Likewise, different neural
cell types may differ in their sensitivity to a lack of functional TPP1.
The selective preservation of retinal ganglion cells could reﬂect a
better ability of these cells to survive without any TPP1 enzyme
compared to other neuronal cells.
Most normal retinal ganglion cells have relatively large cell
bodies and nuclei compared to those of other retinal cell types (e.g.
see Fig. 6). Cell bodies with this type of appearance were rare in the
eyes of the affected dogs (Fig. 5A). This suggests that although these
cells survived until the dogs reached end stage neurologicaldisease, the morphology of the ganglion cell bodies was signiﬁ-
cantly altered.
Substantial TPP1 immunolabeling was associated with the
photoreceptor outer segments of the normal dog retina (Fig. 6A)
and also with the underlying retinal pigment epithelium (RPE) (not
shown). The RPE is known to release substantial amounts of lyso-
somal enzymes into the interphotoreceptor matrix that ensheaths
the photoreceptor outer segments (Adler, 1989; Adler and Evans,
1985; Adler and Martin, 1983). Therefore, it appears likely that
the TPP1 associated with the outer segments was secreted from the
RPE.
We previously reported that localized retinal detachments are
associated with CLN2 disease in the Dachshund model (Whiting
et al., 2015). In untreated dogs, these lesions increase progres-
sively in size and number as the disease progresses to end stage at
10e11months of age. In the present study, we found that TPP1 gene
therapy to the CSF did not prevent the development of these retinal
detachment lesions. However, we found that after 11 months of age
in the treated dogs, as the retina continued to thin and the
photoreceptor cells eventually completely disappeared, the local-
ized separations between the neural retina and the RPE also dis-
appeared, so that the retina again became closely apposed to the
RPE (Figs. 3e5). This suggests that the development of these lesions
in affected dogs is due to abnormal interactions between the
photoreceptor cells and the RPE due to the lack of functional TPP1
enzyme. Since TPP1 protein appears to be present in the inter-
photoreceptor matrix, this enzymemay play a role in mediating the
adhesion of the normal retina to the apical surface of the RPE.
Because administration of a TPP1 gene therapy vector to the CSF
did not appear to inhibit degeneration of any retinal cell types other
than the ganglion cells, it will be necessary to ﬁnd means of more
directly delivering functional TPP1 to the retina in order to prevent
blindness in CLN2 disease. Numerous studies suggest that intra-
vitreal administrationwould be effective in providing TPP1 enzyme
to all cell layers of the retina, thereby delaying or preventing retinal
degeneration (Meyer et al., 2016). Studies are currently under way
to assess whether several alternative means of sustained admin-
istration of TPP1 to the vitreous will be effective in treating the
retinal pathology. If these studies are successful, a combined ocular
R.E.H. Whiting et al. / Experimental Eye Research 146 (2016) 276e282282and CNS treatment may be effective in preserving both neurological
function and vision in this disease.
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